All In Biotech

Drug Trial Radar · NCT02711956

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Dec 2016

Primary completion

Nov 2019

Study completion Nov 2019

Sponsor

Lead sponsor
Zenith EpigeneticsIndustry
Sponsor type
Industry
First posted
Mar 17, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.

Conditions

  • Metastatic Castration-Resistant Prostate Cancer

Interventions

  • ZEN003694Drug

  • EnzalutamideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For Dose Escalation: Incidence of Dose-limiting Toxicities (DLT) to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ZEN003694 in Combination With Enzalutamide.Time frame: Cycle 1 (Day 1 thru Day 28)
  2. For Dose Escalation and Dose Confirmation: Incidence of Treatment-emergent Adverse Events (TEAE) and Treatment-related Serious Adverse Events (SAE)Time frame: Cycle 1 Day 1 to 30 days post last dose

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles Medical Center

    Los Angeles, California

  • University of California San Francisco Medical Center

    San Francisco, California

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Karmanos Cancer Institute

    Farmington Hills, Michigan

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Weill Cornell Medicine - New York Presbyterian

    New York, New York

  • Oregon Health & Science University

    Portland, Oregon

  • Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.